Fred J. Dotzler

EMD Millipore Corp. engages in the provision of laboratory materials, technologies, and services to the life science industry. The company was founded by Jack Bush in 1954 and is headquartered in Burlington, MA.

Crosspoint Venture Partners (Crosspoint Venture Partners) is a venture capital firm founded in 1970 by John B. Mumford. The firm is headquartered in Redwood City, California.

GenoRx, Inc. develops DNA on a chip technology. It develops bioelectronic detection tools that will provide the creation of targeted therapeutics, improved diagnostics and healthier agricultural products. It also provides Biosensing chips to rapidly characterize RNA and DNA for disease diagnosis and scientific research. The company was founded in 2000 and is headquartered in Hayward, CA.

Bayhill Therapeutics, Inc. develops and commercializes therapeutics. Its technology is BHT-DNA. The firm is a clinical-stage biopharmaceutical company leveraging its proprietary therapeutic BHT-DNA platform to develop a pipeline of novel and targeted treatment candidates for autoimmune diseases. Bayhill Therapeutics was founded by Lawrence Steinman, Hideki Garren, William H. Robinson and Paul J. Utz in 2001 and is headquartered in Palo Alto, CA.

Cartilix, Inc. develops surgical devices and associated biomaterials to treat focal cartilage defects in joints. Its technology is used in wound sealing solutions, spinal disc regeneration, and other biological interfaces. The company was founded by Frank Huerta, Norman A. Marcus, and Jennifer Elisseeff in July 2004 and is headquartered in Foster City, CA

Talima Therapeutics, Inc. operated as a drug delivery company. It had developed a micro implant delivery technology for the localized application of small molecule drugs. The firm’s product was in phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the toenails. The company was founded in 2004 and was headquartered in San Carlos, CA.

iScience Interventional Corp. discovers and develops microcatheter and imaging technologies that enable ophthalmologists to deliver site-specific ocular therapies. It encompasses microcatheter-based therapies designed to access anatomical structures within the eye to aspirate ocular fluids or deliver sterile ophthalmic solutions to the eye. The firm addresses the previously unmet need for treatment of sight-threatening diseases with the innovative, minimally invasive iCath™ procedures. The company was founded by Michael F. Nash and Stan Conston in 1999 and is headquartered in Menlo Park, CA.

Vitreoretinal Technologies, Inc. was a pharmaceutical company. It was used to develop and commercialize innovative therapeutic systems for the treatment of serious ocular diseases. The company was founded in July 1999 and was headquartered in Irvine, CA.